MedTrace Logo

Prognostic Impact of Imaging Parameters in Patients With Primary Mitral Insufficiency by Prolapse (COHORTE-IM)

NCT03962023 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2024-03-26

No results posted yet for this study

Summary

Degenerative mitral insufficiency secondary to valve prolapse is the most common valve disease in Western countries. In the absence of specific treatment, it spontaneously progresses to heart failure and death when it is severe. Surgical mitral valve repair (or mitral plastic surgery) is the preferred treatment for primary mitral insufficiency by prolapse in case of severe leakage if associated with clinical and/or echocardiographic markers of poor prognosis (i.e., with high risk of morbi-mortality during their follow-up).

It is therefore essential to refine the risk stratification of these patients in order to identify at-risk patients who should potentially benefit earlier from invasive care (cardiac surgery), or conversely, close monitoring.

A number of echocardiographic and MRI parameters may have been associated with a poorer prognosis.

A cohort of patients with primary mitral insufficiency (MI) will be followed to study the relationships of a set of factors to patient prognosis.

Conditions

  • Mitral Valve Insufficiency

Interventions

OTHER

Echocardiography and MRI

Analysis of echocardiography and MRI parameters

Sponsors & Collaborators

  • University Hospital, Lille

    collaborator OTHER

  • Lille Catholic University

    lead OTHER

Principal Investigators

  • Sylvestre Marechaux, Md, PhD · Lille Catholic University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-04
Primary Completion
2034-09-30
Completion
2034-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03962023 on ClinicalTrials.gov